SETD1A and prostate carcinoma: Additionally, SETD1A is overexpressed and promotes malignant phenotypes in many cancers, such as breast cancer [11, 12], acute myeloid leukemia [13], colorectal cancer [6], gastric cancer [14], hepatocellular cell carcinoma [15] and prostate cancer [16].